Militia Capital Partners LP Has $777,000 Stock Holdings in Cellebrite DI Ltd. $CLBT

Key Points

• Militia Capital Partners LP has increased its stake in Cellebrite DI Ltd. ($CLBT) by 100%, now holding a total of 40,000 shares valued at approximately $777,000.
• Other institutional investors such as Northern Trust Corp and Bank of America Corp DE have also significantly raised their positions in Cellebrite, demonstrating strong investor interest.
• Cellebrite DI reported quarterly earnings of $0.12 per share, surpassing expectations, with revenue increasing 18.4% year-over-year to $113.28 million.

Militia Capital Partners LP grew its stake in shares of Cellebrite DI Ltd. (NASDAQ:CLBT - Free Report) by 100.0% in the first quarter, according to its most recent disclosure with the SEC. The fund owned 40,000 shares of the company's stock after buying an additional 20,000 shares during the period. Militia Capital Partners LP's holdings in Cellebrite DI were worth $777,000 as of its most recent filing with the SEC.

Other large investors have also made changes to their positions in the company. OneDigital Investment Advisors LLC increased its stake in Cellebrite DI by 2.5% in the first quarter. OneDigital Investment Advisors LLC now owns 28,591 shares of the company's stock valued at $556,000 after acquiring an additional 688 shares during the period. Bosun Asset Management LLC increased its stake in Cellebrite DI by 2.5% in the first quarter. Bosun Asset Management LLC now owns 44,376 shares of the company's stock valued at $862,000 after acquiring an additional 1,069 shares during the period. Advisors Asset Management Inc. increased its stake in Cellebrite DI by 24.7% in the first quarter. Advisors Asset Management Inc. now owns 6,133 shares of the company's stock valued at $119,000 after acquiring an additional 1,214 shares during the period. Assetmark Inc. bought a new stake in Cellebrite DI in the first quarter valued at about $33,000. Finally, HighTower Advisors LLC increased its stake in Cellebrite DI by 16.3% in the first quarter. HighTower Advisors LLC now owns 14,485 shares of the company's stock valued at $281,000 after acquiring an additional 2,029 shares during the period. Institutional investors and hedge funds own 45.88% of the company's stock.

Cellebrite DI Stock Up 0.3%

NASDAQ CLBT traded up $0.06 during trading hours on Wednesday, hitting $17.32. The company's stock had a trading volume of 349,899 shares, compared to its average volume of 1,696,119. The stock has a fifty day moving average of $15.27 and a 200 day moving average of $16.94. Cellebrite DI Ltd. has a twelve month low of $13.10 and a twelve month high of $26.30. The firm has a market capitalization of $4.15 billion, a P/E ratio of -22.82, a PEG ratio of 3.17 and a beta of 1.28.

Cellebrite DI (NASDAQ:CLBT - Get Free Report) last announced its quarterly earnings data on Thursday, August 14th. The company reported $0.12 earnings per share for the quarter, beating the consensus estimate of $0.11 by $0.01. Cellebrite DI had a negative net margin of 34.56% and a positive return on equity of 23.92%. The business had revenue of $113.28 million for the quarter, compared to analyst estimates of $112.33 million. During the same period in the prior year, the business posted $0.10 earnings per share. Cellebrite DI's revenue was up 18.4% compared to the same quarter last year. Cellebrite DI has set its Q3 2025 guidance at EPS. FY 2025 guidance at EPS. On average, analysts predict that Cellebrite DI Ltd. will post 0.3 earnings per share for the current year.

Wall Street Analyst Weigh In

A number of research firms recently weighed in on CLBT. Needham & Company LLC lowered their target price on shares of Cellebrite DI from $24.00 to $18.00 and set a "buy" rating on the stock in a research note on Thursday, August 14th. Wall Street Zen cut shares of Cellebrite DI from a "buy" rating to a "hold" rating in a research note on Saturday. Finally, Lake Street Capital decreased their price objective on shares of Cellebrite DI from $24.00 to $22.00 and set a "buy" rating on the stock in a research note on Friday, August 15th. Five research analysts have rated the stock with a Buy rating, According to MarketBeat, Cellebrite DI currently has a consensus rating of "Buy" and a consensus price target of $22.40.

Cellebrite DI Profile

Cellebrite DI Ltd. develops solutions for legally sanctioned investigations in Europe, the Middle East, Africa, the Americas, and the Asia-Pacific. The company's DI suite of solutions allows users to collect, review, analyze, and manage digital data across the investigative lifecycle with respect to legally sanctioned investigations used in various cases, including child exploitation, homicide, anti-terror, border control, sexual crimes, human trafficking, corporate security, cryptocurrency, and intellectual property theft.